Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme Corp.
Update Il y a 4 ans
Étude MK3475-158 : étude de phase 2, évaluant l’efficacité du pembrolizumab dans de nouvelles indications de cancers, chez des patients ayant une tumeur solide avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, os, organes… Elles représentent 90% des cancers. Les cellules cancéreuses sont initialement localisées mais peuvent se propa...
Country
France
organs
Tumeurs solides
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Ltd. (MSD) (UK)
Update Il y a 4 ans
Does montelukast affect the structural proteins in the sputum of patients with asthma?
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with placebo in patients with Type 2 Diabetes. Estudio para evaluar la seguridad y eficacia de la adición de un nuevo fármaco (MK-3102) comparado con placebo en pacientes con Diabetes Mellitus de tipo 2
(1) After 24 weeks, to assess the effect of treatment with MK-3102 compared with placebo on A1C. (2) To assess the safety and tolerability of MK-3102. (1) Al cabo de 24 semanas, evaluar el efe...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
PhII Trial of Pembrolizumab in Advanced Solid Tumors Ensayo clínico de Fase II con pembrolizumab en pacientes con tumores sólidos avanzados
Objective 1: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarker-unselected subjects with any one of multiple types of advance...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude MK-3475-689 : étude de phase 3 comparant l’efficacité du pembrolizumab en monothérapie en traitement néoadjuvant et en association en traitement adjuvant avec celle du traitement standard chez des patients ayant un carcinome épidermoïde de la tête et du cou, à cellules squameuses, localement avancé, résécable et de stade III-IVA.
Les cancers de l’oropharynx, du pharynx et du larynx constituent 90 % des cancers de la tête et du cou et sont favorisés par le tabagisme et l’abus d’alcool. Une infection par certains types de papill...
Country
France
organs
Tête et cou
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
,
Radiothérapie
,
Chirurgie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy
1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C. 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck and Co., Inc
Update Il y a 4 ans
A single dose study of boceprevir in children and adolescents to determine the therapeutic dose
to determine weight based doses of boceprevir for children 17 to 3 years of age.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Serono International
Update Il y a 4 ans
A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active RA, inadequate response to m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 12 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude MK-3475-913 : étude de phase 3 évaluant la sécurité et l’efficacité du pembrolizumab en traitement de première intention chez des patients ayant un carcinome à cellules de Merkel avancé.
Le cancer de la cellule de Merkel est un carcinome cutané. Il doit son nom à la proximité des cellules cancéreuses avec les cellules normales de Merkel de la peau qui contribuent à la sensation tactil...
Country
France
organs
Carcinomes cutanés
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared with Inhaled Corticosteroid Therapy Alone in Patients with Chronic Asthma
1) To demonstrate that treatment with montelukast and mometasone, compared with mometasone alone, results in improvement in FEV1 in patients aged 15 to 85 years with chronic asthma; 2) To determine t...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next